xenon + propofol

This entry refers to a Phase 3 randomized clinical trial conducted at Rigshospitalet, Copenhagen University Hospital, Denmark, comparing the anesthetic effects of inhaled xenon gas and intravenous propofol. Xenon is a noble gas that acts primarily as a non-competitive NMDA receptor antagonist, providing anesthesia and analgesia with minimal hemodynamic impact and rapid emergence. Propofol is a short-acting intravenous anesthetic that primarily acts as a positive allosteric modulator of the GABA-A receptor. The study specifically evaluated these agents as supplementary sedation for elderly patients (aged 60 and older) undergoing knee replacement surgery under spinal anesthesia, focusing on postoperative cognitive function and emergence times. Results indicated that xenon was associated with significantly faster emergence times compared to propofol, although approximately 29% of patients in the xenon group required propofol supplementation to achieve adequate sedation levels.

Brand names

Diprivan

Other names

xenon vs propofol-Rigshospitalet, Denmark-anesthesiaxenon gaspropofolxenonXenon vs propofol